sam486a

SAM486A is a potent and specific small molecule inhibitor of S-adenosylmethionine decarboxylase (SAMDC), a key enzyme in the biosynthesis of polyamines, which are essential for cell proliferation and survival[1][2][3][9][10][12]. SAM486A is a second-generation SAMDC inhibitor, more selective and potent than methylglyoxal bis-guanylhydrazone (MGBG), targeting polyamine metabolism in cancer cells[1][2][3][9]. In phase I and II clinical studies, SAM486A demonstrated antitumor activity in various cancers, including refractory/relapsed non-Hodgkin’s lymphoma and breast cancer, by reducing proliferation and inducing apoptosis[1][2][3][5][6][7]. It has been shown to specifically block spermine synthesis, alter signaling pathways (including STAT and MAPK), and can induce p53-mediated cell death[5][7]. In clinical trials, SAM486A was generally administered intravenously and showed a manageable safety profile, with hematological side effects (anemia, neutropenia, thrombocytopenia) and mild nonhematological toxicities[1][2][3]. The primary developer is Novartis[1][3].